Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients

Authors

  • Yiting Li 1Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Xi Tan 1Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Shu Nie 1Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Xin Tian 2Institute of Dermatology, Guangzhou Medical University, Guangzhou, China, and 3Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China
  • Zhouwei Wu Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

DOI:

https://doi.org/10.2340/actadv.v104.39822

Keywords:

Abrocitinib, Efficacy, Hand eczema, Safety

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol 2020; 34: 4-12.

https://doi.org/10.1111/jdv.16061 DOI: https://doi.org/10.1111/jdv.16061

Marron SE, Tomas-Aragones L, Navarro-Lopez J, Gieler U, Kupfer J, Dalgard FJ, et al. The psychosocial burden of hand eczema: data from a European dermatological multicentre study. Contact Dermatitis 2018; 78: 406-412.

https://doi.org/10.1111/cod.12973 DOI: https://doi.org/10.1111/cod.12973

Quaade AS, Alinaghi F, Dietz JB, Erichsen CY, Johansen JD. Chronic hand eczema: a prevalent disease in the general population associated with reduced quality of life and poor overall health measures. Contact Dermatitis 2023; 89: 453-463.

https://doi.org/10.1111/cod.14407 DOI: https://doi.org/10.1111/cod.14407

Cheng J, Facheris P, Ungar B, Guttman-Yassky E. Current emerging and investigational drugs for the treatment of chronic hand eczema. Expert Opin Investig Drugs 2022; 31: 843-853.

https://doi.org/10.1080/13543784.2022.2087059 DOI: https://doi.org/10.1080/13543784.2022.2087059

Worm M, Thyssen JP, Schliemann S, Bauer A, Shi VY, Ehst B, et al. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol 2022; 187: 42-51.

https://doi.org/10.1111/bjd.21037 DOI: https://doi.org/10.1111/bjd.21037

Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, et al. Oral spleen tyrosine kinase/Janus kinase inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study. J Am Acad Dermatol 2023; 89: 235-242.

https://doi.org/10.1016/j.jaad.2023.04.027 DOI: https://doi.org/10.1016/j.jaad.2023.04.027

Rosenberg FM, Loman L, Schuttelaar MLA. Baricitinib treatment of severe chronic hand eczema: two case reports. Contact Dermatitis 2022; 86: 419-421.

https://doi.org/10.1111/cod.14039 DOI: https://doi.org/10.1111/cod.14039

Zalewski A, Szepietowski JC. Topical and systemic JAK inhibitors in hand eczema: a narrative review. Expert Rev Clin Immunol 2023; 19: 365-373.

https://doi.org/10.1080/1744666X.2023.2174526 DOI: https://doi.org/10.1080/1744666X.2023.2174526

Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem 2018; 61: 1130-1152.

https://doi.org/10.1021/acs.jmedchem.7b01598 DOI: https://doi.org/10.1021/acs.jmedchem.7b01598

Sitaru S, Preis S, Eberlein B. Successful treatment of atopic hand and foot eczema with oral Janus kinase 1 inhibition. Dermatitis 2023; 34: 560.

https://doi.org/10.1089/derm.2022.0030 DOI: https://doi.org/10.1089/derm.2022.0030

Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT, et al. Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay Registry. Acta Derm Venereol 2024; 104: adv19454.

https://doi.org/10.2340/actadv.v104.19454 DOI: https://doi.org/10.2340/actadv.v104.19454

Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022; 86: 357-378.

https://doi.org/10.1111/cod.14035 DOI: https://doi.org/10.1111/cod.14035

Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol 2005; 152: 302-307.

https://doi.org/10.1111/j.1365-2133.2004.06305.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06305.x

Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol 2016; 74: 288-294.

https://doi.org/10.1016/j.jaad.2015.09.062 DOI: https://doi.org/10.1016/j.jaad.2015.09.062

Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015; 54: 715-722

https://doi.org/10.1111/ijd.12645 DOI: https://doi.org/10.1111/ijd.12645

Downloads

Published

2024-06-08

How to Cite

Li, Y., Tan, X., Nie, S., Tian, X., & Wu, Z. (2024). Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients. Acta Dermato-Venereologica, 104, adv39822. https://doi.org/10.2340/actadv.v104.39822

Issue

Vol. 104 (2024)

Section

Short Communication

Categories

License

Copyright (c) 2024 Yiting Li, Xi Tan, Shu Nie, Xin Tian, Zhouwei Wu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC

Funding data